INTRODUCTION The aim of the present study was to compare the therapeutic efficacy of 153Sm-EDTMP and 177Lu-EDTMP in pain palliation in cancer patients with skeletal metastases. MATERIALS AND METHODS Thirty patients (25 M:5 F, mean age: 66.0 ± 14.7 years) of breast/prostate cancer with documented skeletal metastases were recruited prospectively. Twenty patients were considered randomly for tre...

   Developing new bone pain palliation agents is a mandate in handling end-stage cancer patients around the world. Possibly, Lu-177 ethylenediaminetetramethylene phosphonic acid (177Lu-EDTMP) is a therapeutic agent which can be widely used in bone palliation therapy. In this study, 177Lu-EDTMP complex was prepared successfully using synthesized EDTMP ligand and 177LuCl3. Lu-177 chloride was obt...

Background: Owing to its favourable decay characteristics 177Lu [T1/2= 6.71 d, Eβ(max)= 497 keV] is an attractive radionuclide for various therapeutic applications. Ethylene diamine tatramethylene phosphonate (EDTMP) is one of the most widely used ligands which form stable complexes with various radionuclides and all the complexes. Materials and Methods: Enriched 176Lu2O3 was dissolve...

PURPOSE OF THE STUDY With rapid development in the field of nuclear medicine therapy, radiation safety of the personnel involved in synthesis of radiopharmaceuticals has become imperative. Few studies have been done on estimating the radiation exposure of personnel involved in the radio labeling of 177Lu-compounds in western countries. However, data from the Indian subcontinent are limited. We ...

   Developing new bone pain palliation agents is a mandate in handling end-stage cancer patients around the world. Possibly, Lu-177 ethylenediaminetetramethylene phosphonic acid (177Lu-EDTMP) is a therapeutic agent which can be widely used in bone palliation therapy. In this study, 177Lu-EDTMP complex was prepared successfully using synthesized EDTMP ligand and 177LuCl3. Lu-177 chloride was obt...

background: owing to its favourable decay characteristics 177lu [t1/2= 6.71 d, eβ(max)= 497 kev] is an attractive radionuclide for various therapeutic applications. ethylene diamine tatramethylene phosphonate (edtmp) is one of the most widely used ligands which form stable complexes with various radionuclides and all the complexes. materials and methods: enriched 176lu2o3 was dissolved in 0.1 n...

Phosphonic acids labeled with beta-emitting radionuclides are promising radiopharmaceutical drugs for palliative therapy of bone metastases. Currently, the possibility using a new osteotropic compound N,N,N’,N’-ethylenediaminetetrakis (methylene phosphonic acid) lutetium-177 (177Lu-EDTMP) is being studied. The aim work to develop compartment mathematical model kinetics 177Lu in body laboratory ...

introduction:targeted radionuclide therapy (trt) has been demonstrated to be an effective therapeutic tool in patients with disseminated bone metastasis. trt is generally performed with a single radionuclide. in this study we investigated the feasibility of combined trt with a high-energy beta emitter (153sm) and a low energy beta emitter (177lu) in wistar rats. methods: the cocktail complex of...

introduction: bone pain palliation therapy is a mandate in handling end-stage cancer patients. the development of new ligands with higher stability, better pharmacokinetics and lower unwanted tissue uptakes (liver and gi) is still ongoing. methods: in this work lu-177 labeled (3-amino-1-hydroxypropane-1,1-di-yl)-bis-(phosphonate) (177lu-pamidronate; 177lu-pam ), and (3-amino-1-hydroxybutane-1,1...

The biodistribution of 227Th-EDTMP and retention of its daughter nuclide 223Ra were examined. 227Th-EDTMP was found to show high uptake and long-term retention in bone. The clearance of 227Th-EDTMP from blood and soft tissues was rapid and the femur-to-tissue uptake ratios reached more than 100 within 30 min for all tissues except the kidney. Seven and 14 days after injection of 227Th-EDTMP, th...